Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

Journal of Clinical Investigation

Volumn 122, Issue 2, 2012, Pages 575-585

  Drobits, Barbara ^a   Holcmann, Martin ^a   Amberg, Nicole ^a   Swiecki, Melissa ^b   Grundtner, Roland ^a   Hammer, Martina ^a   Colonna, Marco ^b   Sibilia, Maria ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA BETA INTERFERON RECEPTOR 1; CD8 ANTIGEN; IMIQUIMOD; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EFFECTOR CELL; MAST CELL; MELANOMA; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN INFLAMMATION; TUMOR KILLING EFFECTOR CELL; UPREGULATION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMOKINE CCL2; DENDRITIC CELLS; HUMANS; MELANOMA; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASMS, EXPERIMENTAL; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; SKIN; TOLL-LIKE RECEPTOR 7;

EID: 84856521363     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61034     Document Type: Article

References (51)

1. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist. 2008;13(8):859-875.
2. Li VW, Li WW, Talcott KE, Zhai AW. Imiquimod as an antiangiogenic agent. J Drugs Dermatol. 2005;4(6):708-717.
3. Schon MP, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol. 2004;122(5):1266-1276. (Pubitemid 38651103)
4. Hemmi H, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3(2):196-200. (Pubitemid 34141451)
5. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303(5663):1529-1531.
6. Schon MP, Schon M, Klotz KN. The small anti-tumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006;126(6):1338-1347. (Pubitemid 43997917)
7. Kanneganti TD, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature. 2006;440(7081):233-236.
8. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511. (Pubitemid 38931765)
9. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010;234(1):142-162.
10. Asselin-Paturel C, et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med. 2005;201(7):1157-1167. (Pubitemid 40528442)
11. Gibson SJ, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218(1-2):74-86. (Pubitemid 36027092)
12. Thyrell L, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;21(8):1251-1262. (Pubitemid 34185242)
13. Papageorgiou A, Dinney CP, McConkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther. 2007;6(6):872-879. (Pubitemid 351574976)
14. Herzer K, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009;69(3):855-862.
15. Chaperot L, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol. 2006;176(1):248-255. (Pubitemid 43023269)
16. Colisson R, et al. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood. 2009;115(11):2177-2185.
17. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204(6):1441-1451. (Pubitemid 46919881)
18. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol. 2004;173(5):3051-3061. (Pubitemid 39142011)
19. Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M. Immune response modifiers - mode of action. Exp Dermatol. 2006;15(5):331-341.
20. Penna G, Vulcano M, Sozzani S, Adorini L. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Hum Immunol. 2002;63(12):1164-1171. (Pubitemid 36025991)
21. Vermi W, Soncini M, Melocchi L, Sozzani S, Facchetti F. Plasmacytoid dendritic cells and cancer. J Leukoc Biol. 2011;90(4):681-690.
22. Liu C, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008;118(3):1165-1175. (Pubitemid 351364623)
23. Sorrentino R, et al. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. J Immunol. 2010;185(8):4641-4650.
24. Heib V, et al. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood. 2007;110(3):946-953. (Pubitemid 47267433)
25. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007;317(5834):124- 127. (Pubitemid 47056471)
26. Taieb J, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006;12(2):214-219. (Pubitemid 43214748)
27. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M. Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity. 2010;33(6):955-966.
28. Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res. 2005;15(1):24-27.
29. Sato K, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol. 2001;31(11):3138-3146. (Pubitemid 33100505)
30. Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL. Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. Immunity. 2010;33(1):96-105.
31. Stary G, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood. 2009;114(18):3854-3863.
32. Shinbori T, Walczak H, Krammer PH. Activated T killer cells induce apoptosis in lung epithelial cells and the release of pro-inflammatory cytokine TNF-alpha. Eur J Immunol. 2004;34(6):1762-1770. (Pubitemid 39256059)
33. Treilleux I, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004;10(22):7466-7474. (Pubitemid 39561754)
34. Zou W, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001;7(12):1339-1346.
35. Wei S, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005;65(12):5020-5026. (Pubitemid 40827308)
36. Kato A, et al. Dexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cells. J Immunol. 2009;182(11):7233-7243.
37. Sawaki J, et al. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways. Int Immunol. 2007;19(3):311-320. (Pubitemid 46344696)
38. Ooi T, et al. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol. 2006;154(1):72-78. (Pubitemid 43381323)
39. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood. 2010;115(10):1949- 1957.
40. Jahrsdorfer B, et al. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood. 2009;115(6):1156-1165.
41. Inglefield JR, et al. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res. 2008;28(4):253-263. (Pubitemid 351591448)
42. Monleon I, et al. Differential secretion of Fas ligandor APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol. 2001;167(12):6736-6744. (Pubitemid 33144163)
43. Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J Biol Chem. 2003;278(42):41173- 41181. (Pubitemid 37280943)
44. Shinkai Y, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68(5):855-867.
45. Muller U, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918-1921. (Pubitemid 24245635)
46. Adachi O, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 1998;9(1):143-150. (Pubitemid 28361303)
47. Lu B, et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med. 1998;187(4):601-608. (Pubitemid 28093362)
48. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010;140(2):268-279.
49. Holcmann M, et al. Skin inflammation is not sufficient to break tolerance induced against a novel antigen. J Immunol. 2009;183(2):1133-1143.
50. Uze G, et al. Domains of interaction between alpha interferon and its receptor components. J Mol Biol. 1994;243(2):245-257. (Pubitemid 24331979)
51. Ma F, Zhang J, Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol. 2010;7(5):381-388.